Corbus Pharma Provides an Update on Their Clinical Trial Programs

Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals provides and update on his company’s clinical trial programs.

Lenabasum is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies for systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.